Disarm Therapeutics, Inc.

Eli Lilly and Company

Andrew Simon Brearley

Rajesh Devraj

Todd Bosanac

Robert Owen Hughes

Jonathan Bentley

Shelley Anne Parrott

Richard Andrew Jarjes-pike

Frederic Jacques Marlin

Daniel Silva

Richard Andrew Jarjes-Pike

Sophie Catherine Cooper

The present disclosure provides compounds and methods useful for inhibiting SARM1 and/or treating and/or preventing axonal degeneration.

Inhibitors of SARM1

The present disclosure provides compounds of formula (I) and methods useful for inhibiting SARM1 and/or treating and/or preventing axonal degeneration.

Indazole derivatives as inhibitors of SARM1

The present disclosure provides compounds and methods useful for inhibiting SARM1 and/or treating and/or preventing neurodegenerative disease or axonal degeneration. The provided SARM1 inhibitors may reduce or inhibit binding of NAD+ by SARM1. Alternatively, provided SARM1 inhibitors bind to SARM1 within a pocket comprising one or more catalytic residues (e.g., a catalytic cleft of SARM1).

Growing community of inventors

Abingdon, United Kingdom

Andrew Simon Brearley